Psoriasis: trials for referral
329 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
329 trials shown
No phase1 site
RecruitingHungary
NCT07746583
A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical Practice
Janssen-Cilag Kft.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT04864886
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
National Institute of Allergy and Infectious Diseases (NIAID)
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 41 site
RecruitingUnited States
NCT07654751
A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
Janssen Research & Development, LLC
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 358 sites
RecruitingArgentina, Australia, Belgium, Brazil, China, Germany
NCT06663332
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Janssen Research & Development, LLC
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingFrance
NCT07532226
A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants
Janssen-Cilag Ltd.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govNo phase20 sites
RecruitingRomania
NCT07582783
A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania
Janssen Research & Development, LLC
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govNo phase21 sites
RecruitingItaly
NCT07220824
A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting
Janssen Research & Development, LLC
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 26 sites
Not yet recruitingCanada
NCT07914231
A Study to Assess the Safety and Effectiveness of COL-5671-PRO Capsules in Adults With Moderate-to-Severe Plaque Psoriasis
Coultreon Biopharma
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 10 sites
Not yet recruiting
NCT07908641
Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation
Amgen
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 12 sites
RecruitingAustralia
NCT07736586
A Study of HL40626S Tablets in Healthy Adults
HighsLab Therapeutics Inc.
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingGermany
NCT02719314
Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis
Prof Dr Frank Buttgereit
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 3401 sites
RecruitingArgentina, Australia, Belgium, Bulgaria, Brazil, Canada
NCT07116967
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bristol-Myers Squibb
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingCanada
NCT05994976
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
Innovaderm Research Inc.
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07871721
A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)
Takeda
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 3131 sites
RecruitingArgentina, Belgium, Brazil, Canada, China, Colombia
NCT06979453
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Bristol-Myers Squibb
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingGermany
NCT01848028
PsoBest - The German Psoriasis Registry
Universitätsklinikum Hamburg-Eppendorf
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited Kingdom
NCT07166315
Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
Adelphi Real World
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 31 site
Not yet recruitingEgypt
NCT07892339
Efficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis.
Cairo University
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingAustralia
NCT07850310
A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)
Merck Sharp & Dohme LLC
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 362 sites
RecruitingArgentina, Australia, Brazil, Canada, Germany, Spain
NCT04772079
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
Bristol-Myers Squibb
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govNo phase2 sites
By invitation onlySweden
NCT07352696
Combined High-Intensity Aerobic Training and Resistance Training in Psoriatic Arthritis
Vastra Gotaland Region
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 242 sites
RecruitingCanada, Germany, Spain, United States
NCT07449702
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Oruka Therapeutics, Inc.
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingNetherlands
2026-525575-22-00
A first in human study of the safety, pharmacokinetics and pharmacodynamics of KLR-003 in healthy participants and patients with immune mediated diseases.
Klear Bio Inc.
Registry updated 23 Oct 2026
Registry record: EU CTISPhase 41 site
RecruitingEgypt
NCT07352306
Topical Diacerein in Psoriasis Vulgaris
Alaa Ashraf Muhammad Helal
Registry updated 22 Oct 2026
Registry record: ClinicalTrials.govNo phase82 sites
RecruitingCanada, Israel, Italy, Puerto Rico, United States
NCT02418442
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Duke University
Registry updated 21 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingEgypt
NCT07736651
Anti Inflammatory Diet With Physical Therapy on Psoriasis
Mahmoud Usama Mahmoud Ahmed
Registry updated 21 Oct 2026
Registry record: ClinicalTrials.govNo phase0 sites
Not yet recruiting
NCT07885345
Definition of Novel Optoacoustic Biomarkers of Psoriasis and Psoriatic Arthritis
University of Erlangen-Nürnberg Medical School
Registry updated 21 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingChina
NCT07879885
An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis
Hansoh BioMedical R&D Company
Registry updated 20 Oct 2026
Registry record: ClinicalTrials.govNo phase0 sites
Not yet recruiting
NCT07881783
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
Novartis Pharmaceuticals
Registry updated 20 Oct 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07752108
A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis
Takeda
Registry updated 20 Oct 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States71 open trials
- China50 open trials
- France37 open trials
- Germany25 open trials
- Italy22 open trials
- Canada19 open trials
- Spain18 open trials
- Poland16 open trials
- Egypt16 open trials
- United Kingdom13 open trials
- Belgium13 open trials
- Hungary9 open trials
- South Korea8 open trials
- Czechia8 open trials
- Mexico8 open trials
- Netherlands8 open trials
- Australia7 open trials
- Japan7 open trials
- Bulgaria7 open trials
- Portugal6 open trials
- Taiwan6 open trials
- Pakistan6 open trials
- Argentina5 open trials
- Sweden5 open trials
- New Zealand5 open trials
- Greece5 open trials
- Switzerland5 open trials
- Denmark5 open trials
- Brazil4 open trials
- Norway4 open trials
- Israel4 open trials
- Romania4 open trials
- Singapore4 open trials
- Hong Kong SAR China4 open trials
- Costa Rica4 open trials
- Thailand3 open trials
- Austria3 open trials
- Puerto Rico2 open trials
- Croatia2 open trials
- Estonia2 open trials
- Latvia2 open trials
- India2 open trials
- Colombia1 open trials
- Chile1 open trials
- Slovakia1 open trials
- Saudi Arabia1 open trials
- Ireland1 open trials
- Jordan1 open trials
- Philippines1 open trials
- Indonesia1 open trials
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, China
0 trials · 145 publications · ROR
Chinese Academy of Medical Sciences Dermatology Hospital
Nanjing, China
0 trials · 44 publications · ROR
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
5 trials · 47 publications · ROR
Fraunhofer Institute for Translational Medicine and Pharmacology
Frankfurt am Main, Germany
0 trials · 47 publications · ROR
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Bologna, Italy
0 trials · 38 publications · ROR
Manchester Academic Health Science Centre
Manchester, United Kingdom
0 trials · 111 publications · ROR
Manchester University NHS Foundation Trust
Manchester, United Kingdom
1 trials · 58 publications · ROR
NIHR Manchester Biomedical Research Centre
Manchester, United Kingdom
0 trials · 106 publications · ROR
The University of Texas Southwestern Medical Center
Dallas, United States
1 trials · 170 publications · ROR
University of California, San Francisco
San Francisco, United States
5 trials · 140 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
No registry change in the last 7 days.
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
No phaseEnded 16 Oct 2026
Completed603 participants
NCT05908240
Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis
Phase 3Ended 3 Sept 2026
Completed21 participants
NCT05565560
A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis
Phase 4Ended 2 Sept 2026
Completed42 participants
NCT06013969
A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares
Phase 3Ended 19 Aug 2026
Completed539 participants
NCT07357831
A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects
Phase 2Ended 13 Aug 2026
Completed18 participants
2025-523051-64-00
A trial to explore the efficacy and safety of IDOR-1117-2520 in adults with moderate to severe chronic plaque psoriasis, with or without psoriatic arthritis.
Phase 3Ended 12 Aug 2026
Completed51 participants
NCT06088199
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
Phase 3Ended 23 Jul 2026
Phase 3Ended 21 Jul 2026
Completed1466 participants
NCT04036435
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
Phase 1Ended 20 Jul 2026
Completed96 participants
2025-522571-28-00
A study to evaluate how well single and multiple doses of O3R-5671-PRO are tolerated in healthy adult subjects
Phase 3Ended 10 Jul 2026
Completed18 participants
NCT06323356
A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Phase 3Ended 2 Jul 2026
Completed453 participants
NCT04936308
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
Phase 1Ended 1 Jul 2026
Phase 1Ended 22 Jun 2026
Completed114 participants
NCT07254325
Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers
Phase 4Ended 14 Jun 2026
Completed40 participants
NCT07432815
Treatment of Psoriasis With Depression and/or Anxiety With Methotrexate vs Combined Methotrexate and Antidepressant
No phaseEnded 11 Jun 2026
Phase 3Ended 3 Jun 2026
Completed553 participants
NCT06624228
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
Phase 3Ended 1 Jun 2026
Completed281 participants
NCT06588283
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Phase 3Ended 26 May 2026
Completed1131 participants
NCT04009499
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Phase 1Ended 22 May 2026
No phaseEnded 14 May 2026
Completed302 participants
NCT06714461
A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia
Phase 1Ended 5 May 2026
Completed18 participants
2025-523430-14-00
A study to compare how the body absorbs different formulations of a new medicine, and how food affects drug absorption, in healthy participants
Phase 1Ended 30 Apr 2026
Completed22 participants
NCT07340216
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
Phase 1Ended 30 Apr 2026
Phase 3Ended 23 Apr 2026
Completed279 participants
NCT06588296
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Phase 3Ended 22 Apr 2026
Completed606 participants
NCT06973291
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
Phase 2Ended 10 Apr 2026
Phase 3Ended 1 Apr 2026
Phase 1Ended 30 Mar 2026
Completed15 participants
2025-522446-51-00
Assessment of the safety and effects on the body of investigational products when used on psoriatic skin
Phase 2Ended 27 Mar 2026
Phase 4Ended 19 Mar 2026
Phase 3Ended 19 Mar 2026
Completed336 participants
NCT06398652
Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis
Phase 1Ended 18 Mar 2026
Completed575 participants
NCT07546214
A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.
Phase 4Ended 17 Mar 2026
Phase 1Ended 11 Mar 2026
Completed44 participants
2025-520514-64-00
Phase 1 study with topical cream RLS-1496 in patients with plaque psoriasis or Eczema
Phase 3Ended 9 Mar 2026
Completed202 participants
NCT07008547
To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis
No phaseEnded 5 Mar 2026
Completed6967 participants
NCT07580092
Construct Validity and Responsiveness of EQ-5D-3L and EQ-5D-5L in Patients With Inflammatory Joint Disease
No phaseEnded 2 Mar 2026
No phaseEnded 1 Mar 2026
Completed460 participants
NCT07277491
Assessment of Nutritional Status in Rheumatic Diseases and Association to Disease Activity
No phaseEnded 28 Feb 2026
Phase 4Ended 6 Feb 2026
Completed16 participants
NCT03988439
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
No phaseEnded 6 Feb 2026
Completed101 participants
NCT05631223
Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA)
Phase 2Ended 29 Jan 2026
Phase 3Ended 26 Jan 2026
Completed244 participants
NCT07746479
A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis )
No phaseEnded 22 Jan 2026
Completed2376 participants
NCT02786186
A Registry of Patients With Moderate to Severe Plaque Psoriasis
Phase 1Ended 6 Jan 2026
Phase 4Ended 5 Jan 2026
Completed385 participants
NCT04306315
Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight
No phaseEnded 5 Jan 2026
Completed16 participants
NCT06555562
Activating the Cholinergic Anti-Inflammatory Pathway in Healthy Volunteers and People With Inflammatory Arthritis
No phaseEnded 31 Dec 2025
No phaseEnded 31 Dec 2025
No phaseEnded 31 Dec 2025
Completed70 participants
NCT07386717
Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis
Phase 3Ended 22 Dec 2025
Completed508 participants
NCT04314544
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
No phaseEnded 19 Dec 2025
No phaseEnded 18 Dec 2025
Completed70 participants
NCT01969188
A Study of Novel Immune Modulating Biomarkers in Patients With Spondyloarthritis With Axial Involvement
Phase 3Ended 18 Dec 2025
Completed862 participants
NCT06588738
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
Phase 3Ended 12 Dec 2025
No phaseEnded 11 Dec 2025
Completed60 participants
NCT05590247
Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis
No phaseEnded 11 Dec 2025
Phase 2Ended 6 Dec 2025
Phase 3Ended 5 Dec 2025
Early Phase 1Ended 1 Dec 2025
Not medical advice. fetched 4 Nov 2026